DMD Carrier Screening (79 Exons) in UAE | AED 3500 | DHA Licensed

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% diagnostic sensitivity for exon-level deletions and duplications via ISO 9001:2015 accredited MLPA and NGS reflex (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic post-test result interpretation by DHA-licensed genetic counselors.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The DMD Carrier Screening (79 Exons) accurately detects deletions and duplications across all 79 exons of the dystrophin gene using gold-standard MLPA (Multiplex Ligation-dependent Probe Amplification) with reflex to Next-Generation Sequencing for confirmation. This comprehensive assay is essential for assessing female carrier status in families with a history of Duchenne muscular dystrophy.

Feature	Our Test (MLPA + NGS Reflex)	Standard PCR‑Only Screening
Precision	>99% sensitivity for large rearrangements	Limited to known point mutations; misses large deletions
Method	MLPA + Next‑Gen Sequencing Reflex	Conventional PCR / Sanger sequencing
Speed	7–10 working days	Up to 14 working days

Physician Insight & Safety Protocols

“As a DHA‑licensed Consultant Medical Genetics, I emphasize that DMD carrier screening is a critical tool for reproductive planning. However, results must be interpreted within the full context of family history, creatine kinase levels, and comprehensive genetic counseling. A negative screen does not eliminate residual risk, and clinical correlation remains paramount. Always involve a clinical geneticist before making irreversible family planning decisions.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory Information

No special preparation is required for this blood test. However, please inform the laboratory if you have received a blood transfusion within the past two weeks or if you have any known coagulation disorders. Results should always be reviewed with a qualified healthcare provider.

Exclusion Criteria & Red Flags

Active infection or fever (>38°C) – reschedule the blood draw.
Known pregnancy: this blood test only assesses maternal carrier status; invasive prenatal diagnosis (amniocentesis/CVS) may be required. Contact your obstetrician.
Recent blood transfusion (<2 weeks) may interfere with MLPA results – inform the lab before collection.
Emergency Red Flags: Sudden muscle weakness, difficulty climbing stairs, elevated CK levels, or cardiac symptoms (palpitations, shortness of breath) require immediate medical attention. Proceed to the nearest emergency room.

Patient FAQ & Clinical Guidance

1. What is DMD carrier screening and who should consider it?

DMD carrier screening detects mutations in the dystrophin gene to identify females who may pass Duchenne muscular dystrophy to their children. It is recommended for women with a family history of DMD, unexplained elevated creatine kinase levels, or those planning a family who want to understand their carrier status.

2. How accurate is the 79‑exon MLPA test compared to other methods?

The 79‑exon MLPA test achieves over 99% analytical sensitivity for large deletions and duplications, significantly outperforming standard PCR which may miss up to 70% of dystrophin mutations. The addition of NGS reflex confirms findings and detects rare sequence variants.

3. Do I need a doctor’s prescription for this test in the UAE?

A valid doctor’s prescription is generally required for carrier screening tests in the UAE. Exceptions include surgery clearance, pregnancy‑related genetic counseling, or travel health certificates where regulations may allow direct access. It is advisable to consult with our team for specific requirements.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and handled with strict confidentiality in accordance with UAE healthcare data protection standards.

Clinical & Logistical Metadata

Test Name	DMD Carrier Screening (79 Exons) – MLPA & NGS Reflex
Price (AED)	3,500
Turnaround Time	7–10 working days
Sample Type / Matrix	Peripheral whole blood (EDTA tube)
Methodology Used	MLPA (Multiplex Ligation-dependent Probe Amplification) + Next-Generation Sequencing Reflex
ICD-10-CM Code	Z13.71
LOINC Code	21629-9
DHA Facility License & Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE